DDInter1632 DDInter1658
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma,
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Salbutamol {u} (Compound) resembles {v} (Compound) Terbutaline
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Salbutamol {u} (Compound) resembles {v} (Compound) Clenbuterol
Salbutamol {u} may lead to a major life threatening interaction when taken with {v} Levobunolol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Salbutamol {u} (Compound) treats {v} (Disease) asthma
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
Salbutamol {u} (Compound) palliates {v} (Disease) allergic rhinitis
Salbutamol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Salbutamol {u} (Compound) causes {v} (Side Effect) Asthenia
Salbutamol (Compound) resembles Terbutaline (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Salbutamol (Compound) resembles Clenbuterol (Compound)
Salbutamol may lead to a major life threatening interaction when taken with Levobunolol
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Salbutamol (Compound) treats asthma (Disease)
Salbutamol (Compound) binds ADRB1 (Gene)
Salbutamol (Compound) palliates allergic rhinitis (Disease)
Salbutamol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Salbutamol (Compound) causes Asthenia (Side Effect)